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Abstract—Hematopoietic stem cells (HSC) are defined by
the International Society of Hematotherapy and Graft
Engineering (ISHAGE) as those at low side scatter, positive
for CD34 and CD45dim for their numeration with flow
cytometry. However, we found that these CD34+ cells
increase their granularity and size following in vitro
culture, which was exhibited in flow cytometry as more
events at higher side scatter and forward scatter. To further
determine whether such a change in the cell event
distribution is related to HSC differentiation, HSC markers
and differentiation markers of in vitro-cultured HSC were
detected by flow cytometry at different side scatter and
forward scatter levels using modified ISHAGE gating
strategies.  The results revealed that cultured HSC with
higher side scatter have a lower percentage of cells positive
for HSC markers and a higher percentage of differentiation
makers, while those with higher forward scatter have a
higher percentage of differentiation makers but a slightly
higher percentage of stem cell markers, suggesting that side
scatter and forward scatter levels of cultured HSC correlate
with the differentiation level of these cells.
Index Terms—Hematopoietic stem cells, Flow cytometry,
Cell culture, Differentiation.
I. INTRODUCTION
Pre-cultured hematopoietic stem cells (HSC) from
blood and bone marrow are small round, and single-
nucleated [1], [2]. When they are examined by flow
cytometry, these CD34 positive events demonstrate low
side scatter by dot plot analysis [3]-[5], indicating their
low granularity. Based on these characteristics, an HSC
numeration method made by ISHAGE has been broadly
accepted and applied in clinical determination of HSC
[3]-[5]. However, following culture with certain
cytokines, these cells become larger and more irregular.
In flow cytometry, these cells are shown as the events
at higher side scatter for their higher granularity and
higher forward scatter for their increased size. In order to
determine if these events represent more differentiated
HSC and if side and forward scatters of flow cytometry
can be used to evaluate differentiation states of HSC
following in vitro culture, the events at different levels of
side scatter and forward scatter were analyzed by
examining the expression of stem cell markers and
differentiation markers in this study.
During the development, almost all HSC differentiate
into either myeloid linage or lymphoid linage. In the very
early stage of differentiation, the pluripotent HSC gains
CD33 marker to mainly become a myeloid stem cell or
Yongxin Zhang, Corresponding author, Zyxell Inc. Carrollton, Texas,
USA.
Yongxin Zhang, Farhang Farhangfar, Leonard Giblin, Francesca
Vitelli, and Donnie Rudd, Regenetech, Inc., Houston, Texas, USA
David Wolf, NASA, Houston, Texas, USA
Yu Zhou, Methrogen Inc., Houston, Texas, USA
gains CD38 to lymphoid stem cell. CD33 exists at
different levels on myeloid cells leucocytes at most
maturation stages. The myeloid commitment of
hematopoietic progenitors is characterized by the
progressive loss of CD34 expression accompanied by the
acquisition of CD33 expression.[6]-[8] CD33 expression
continues along the myelomonocytic pathway of
differentiation, even though its expression is highly down
regulated at the ending stage of some cells [6]-[8]. CD38
is expressed on lymphoid stem cells and most mature
lymphocytes though the expression on T-lymphocytes
could also be down-regulated at various levels [9]-[11].
Therefore, CD33 and CD38 could be the ideal markers to
evaluate early HSC differentiation.
II. MATERIALS AND METHODS
A.Cell culture:
G-CSF mobilized peripheral HSC (AllCells, LLC.
Emeryville, CA) were cultured with CellGro®Stem Cell
Expansion Media (CellGenix, Inc., Catalog number:
2001) containing 10ng/ml TPO (Peprotech, Inc. Rocky
Hill, NJ. Catalog number: 300-18), 50ng/ml SCF
(Peprotech, Inc. Rocky Hill, NJ. Catalog number: 300-
07), 50ng/ml Flt3 L (Peprotech, Inc. Rocky Hill, NJ.
Catalog number: 300-19), 10ng/ml IL-3 (StemCell
Technologies Inc. Vancouver, BC, Canada. Catalog
number: 02603) and 1X PSA (Life Technologies
corporation, Carlsbad, CA) in 5% CO2 incubator at 37oC
for 3 days, then diluted by 1:4 with the same media for
further 3 days’ culture.
B. Flow Cytometry
On the day 0, day 3 and day 6 following the culture, cells
for each sample were washed twice and re-suspended in
100µL staining buffer (1x PBS / 0.5% BSA). 20µL Fc
receptor blocking antibody (Miltenyi Biotec Inc. Auburn,
CA) was added into each reaction and incubated for 10
minutes at room temperature. Then 1ml of staining buffer
was added to each reaction and after mixing, cells were
aliquoted into different tubes for staining with different
antibodies, including CD45, CD34 and CD38 triple
staining, CD45, CD34 and CD33 triple staining, CD45,
CD34, CD38 and CD33 single staining and unstained
and isotype controls. Fluorescence-labeled CD45 and
CD38 antibodies and their isotype controls used for the
staining were purchased from BD Biosciences Inc.(San
Jose, CA).  Antibody to CD34 and its isotype control
were purchased from Miltenyi Biotec.  Antibody to
CD33 and its isotype control were purchased from
ebioscience, Inc. (San Diego, CA). ISHAGE stem cell
numeration protocol [12] was slightly modified for three
color flow cytometry and employed for the event gating
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in this study. In brief, 2 more dot plots for the third
antigen detection (color) and 1 more dot plot for the
double positive population of CD34 and CD33 or CD34
and CD38 were added as shown in Figure 1.
C. Statistics:
For the analysis of FS levels (levels 1-4) and SS levels
(levels 1-4) on the FS/SS dot plot, events were gated into
4 areas (Fig.2a for pre-culture and 2b for post culture), in
which the main population was equally divided into 3
areas and the remaining higher part forms the 4th area.
For side scatter level analysis and forward scatter level
analysis, side scatter and forward scatter versus FL1-
FITC or FL2-PE were respectively used (Figures 3 and
4). The CD33 and CD38 positive rates of the events in
each area was used to determine the relationship of the
cell differentiation and the cell size on Forward scatter or
cell granularity on side scatter and the relationship was
analyzed by correlation. The correlation coefficient (r)
and P values were obtained from z test. The CD33 and
CD38 positive rates at different levels of side scatter or
forward scatter were compared by ANOVA. SAS-
Statview was used for the statistical analysis.
III. RESULTS
A. Characterization of pre-cultured HSC.
Pre-culture cells were triple-stained and analyzed with
the modified ISHAGE protocol. The results showed that
89% of the cells are positive for CD45dim, 81.10% for
CD133, 87.58% for CD34, 76.34% double positive for
CD34 and CD133, 44.36% for CD38, 44.18% double
positive for CD34 and CD38, 0.86% for CD33 and
0.48% double positive for CD34 and CD33. Based on the
area compartmentalization shown in Fig. 3 and Fig.4,
CD33 and CD38 positive percentages at the different
levels of side scatter and forward scatter are shown in
Table 1.
From Table 1, following characters of our primary
sample can be seen: (1) Very few of the cells were
CD33+. Only the events in area 4 of both side and
forward scatter were slightly over our positive threshold
(1.00%), all remaining numbers fell in the negative
territory. (2) In the areas 4 of both side and forward
scatter, the percentages of total CD34 positive cells,
CD34 positive but CD33 negative cells and CD34
positive but CD38 negative cells are consistently lower
than those in other corresponding areas (areas 1-3),
indicating the majority of primitive HSC were located in
the main population (areas 1-3 for both side and forward
scatters) and non-HSC cells in our sample were mainly in
areas 4. (3) CD38 positive percentages are negatively
Fig 1. Flow Cytometry of pre-expansion CD34+ magnetically
selected mobilized peripheral blood cells (HSCs) using a
modified ISHAGE gating strategy.  Samples were triple stained
using anti CD45PerCP, CD34PE, and CD33 or CD38FITC.
Thresholds were set with positive events in the negative control
set to less than 1% using unstained cells for CD45 and
CD45PerCP/CD34PE isotype control/CD33 or CD38FITC
isotype control for the other markers.  Single stained cells were
used for compensation.  (A) Mononuclear Cells Gated based on
Forward and Side Scatter (FSC and SSC).  Panels B-H were
based on this gate and showed (B) CD45PerCP staining, (C)
CD33 or CD38FITC+ Cells, (D) CD34PE+ Cells,
(E)CD45+CD33 or CD38+, (F)CD45+CD34+,
(G)CD45+CD34+CD33 or CD38+ (Double positive),
(H)CD45+CD34+CD33 or 38- (Single positive).
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Fig 2. Comparison of Light Scattering Properties of Pre and Post Expansion Cells.  The change in Forward and Side Scatter of HSCs
from day-0 (A) today 6 (B) was analyzed.  To analyze the events at different side scatter levels (1-4) and forward scatter levels (1-4), the
main cell population was equally divided into 3 subpopulations respectively on Forward Scatter (gates a - c) and Side Scatter (gates 1 –
3), and the events above main population form gate d on forward scatter and gate 4 on side scatter.
Fig 3. CD33 Distribution by Forward Scatter.  (A) CD45PerCP+ (gate 11) cells were analyzed in panels B and C.  Distribution of
CD33FITC (B) and CD34PE (C) stained cells by Forward Scatter.  (D) The distribution of CD33 and CD34 expressing cells as
determined by panels B and C based on Forward and Side Scatter.
Fig 4. CD33 Distribution by Side Scatter (A) CD45PerCP+ (gate 11) cells were analyzed in panels B and C.  Distribution of CD33FITC
(B) and CD34PE (C) stained cells by Side Scatter.  (D) The distribution of CD33 and CD34 expressing cells as determined by panels B
and C based on Forward and Side Scatter.
Table 1. CD33 and CD38 positive percentages of uncultured HSC at the different levels of side and forward scatter
Scatter Areas CD33+(%) CD34+CD33-(%) CD34+(%) CD38+(%) CD34+CD38-(%)
Side 1 0.48 90.24 90.71 58.37 33.68
2 0.30 95.40 95.44 49.36 46.37
3 0.32 91.75 92.07 44.91 45.34
4 1.32 44.13 45.45 29.46 16.46
Forward 1 0.12 87.23 87.35 41.88 46.62
2 0.21 93.25 93.46 50.13 43.35
3 0.50 90.69 91.19 54.58 35.54
4 1.34 47.16 48.49 31.67 12.46
correlated to side scatter levels (r=-0.68, P<0.05)
as shown in Figure 5, but the percentages for other
markers are not significantly correlated to either
side scatter levels or forward scatter levels. The
negative correlation between CD38 expression
and side scatter levels reflects that most of
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lymphoid stem cells in our uncultured samples
have low level of granularity.
B. The correlations between CD34, CD33 or CD38
expression and side scatter on HSC in vitro
cultured for 6 days (Figure 6).
Different from non-cultured HSC (not shown), CD33
expressions in total cells (Figure 6A) and in CD34
positive cells (Figure 6B) following 6 days’ culture were
remarkably at quite high levels on side scatter, and both
CD33 positive percentage and CD33 and CD34 double
positive (CD34+CD33+) percentage significantly
increased as the side scatter level increased, the positive
correlations are shown in Figure 6A and 6B (r=0.787 and
0.719, P<0.01, respectively).  In contrast, the percentages
of CD34+CD33- events and total CD34 positive events
were negatively correlated to the side scatter levels
(Figure 6C and 6D, r=-0.951 and -0.688, P<0.01,
respectively). When the positive percentages on different
levels of side scatter were compared, CD33+,
CD34+CD33- and total CD34+ did not show significant
differences between level 1 and level 2 while all marker
positive percentages exhibited significant differences
between all other two levels. These results suggested that
following the in vitro culture some HSC differentiated to
granular cells exhibiting on higher side scatter and with
the expression of CD33 in flow cytometry, and the
population at lower side scatter contains more primitive
HSC.
Figure 5. Correlation between CD38 positive percentages and
side scatter levels in pre-culture CD34+ HSC isolated from G-
CSF mobilized peripheral blood. Cells were triple-stained for
CD45, CD34 and CD38 prior to detection with flowcytometer.
A flowcytomtric dot plot (SS/FS) was divided into 4 areas and
scaled from 1 to 4 to show the scatter levels. A correlation chart
was plotted by CD38 positive percentage versus side scatter
levels.
Compared to uncultured HSC, CD38 positive (CD38+)
event distribution in 6 days’ cultured cells is completely
changed. The CD38+ percentage is positively correlated
to side scatter level (Figure 6E, r=0.887, P<0.01) instead
of as the negative correlation shown in uncultured HSC
(Figure 5).  The reduction of CD38+ cells from day 0 to
day 6 following the culture mainly occurred in areas 1
and 2 of side scatter grids, suggesting that CD38 positive
lymphoid stem cells might not expand very much in our
culture system but become more irregular or more
granular. This could lead to an increase in more primitive
HSC at lower side scatter.
CD38+, CD34 and CD38 double positive
(CD34+CD38+) and CD34 positive but CD38 negative
(CD34+CD38-) percentages were correlated to side
scatter (Figure 6E-6G, r=0.887, 0.884 and 0.805, P<0.01,
respectively)  in the same pattern as were CD33+,
CD34+CD33+ and CD34+CD33-, respectively. The results
showed that unlike with CD33, no significant difference
could be found between side scatter level 1 and side
scatter level 2 for all CD38+, CD34+CD38+ and
CD34+CD38- percentages. This further confirms that the
cultured HSC at the lower side scatter are less
differentiated.
Similar to their correlation with side scatter, CD33+,
CD38+, CD34+CD33+ and CD34+CD38+ percentages
were positively correlated to forward scatter levels
(Figure 7A, 7B, 7E and 7F, r=0.873, 0.855, 0.718 and
0.718, P<0.01, respectively), while the percentages of
CD34+CD33- and CD34+CD38- events were negatively
correlated to the side scatter levels (Figure 6C and 6D,
r=-0.89 and -0.74, P<0.01, respectively).  However, the
total CD34 positive percentages were not correlated to
forward scatter levels and no significant differences of
CD34 positive percentages among different forward
scatter levels were found, suggesting that the size of
CD34+ cells is variable but the larger ones are more
likely to be differentiated. CD33+, CD34+CD33-, CD38
and CD34+CD38- percentages did not show significant
differences between side scatter levels 1 and 2. But all
these cell types were at their highest percentages in side
scatter level 4. This is further support that the cells at
higher side scatter are more differentiated.
Only 4 samples from culture on day 3 had enough
cells for all flow cytometric examinations. All
correlations (r=0.624-0.832, P<0.05 or 0.01) from the
samples on day 3 were consistent with those on day 6
except that no significant correlation was found between
CD38+ percentages and side scatter levels.
III. DISCUSSION
Flow cytometry, as a standard HSC numeration
method, has been broadly applied in clinics [13]-[15] .
ISHAGE defined the HSC as being CD34+, CD45dim and
at low side scatter according to the performance of HSC
events on flow cytometric dot plots [16]. In our modified
ISHAGE protocol, cells were triple-stained, two more
dot plots for the third stain and the dot plot for triple
positive event detection were added.  Multiple gates in
plots of side scatter versus forward scatter formed grids
to be used in further analysis. When this system was used
to examine the uncultured HSC, it was found that CD33+
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Figure 6. CD34, CD33 and CD38 positive percentages correlate with event levels on side scatter. CD34-positive HSC isolated from G-
CSF mobilized peripheral blood were in vitro cultured for 6 days. Cells from 10 cultures were triple-stained for flow cytometric detection
of CD45, CD34 and CD33 or CD38. A flow cytomtric dot plot (SS/FS) was divided into 4 areas on the side scatter and scaled from 1 to 4
to show the scatter levels. Correlation charts were plotted by cell marker positive percentages versus side scatter levels. A: Positive
correlation between CD33 positive percentages and the event levels on side scatter; B: Positive correlation between CD34 and CD33
double positive percentages and the event levels on side scatter; C: Negative correlation between CD34 positive but CD33 negative
percentages and the event levels on side scatter; D: Negative correlation between total CD34 positive percentages and the event levels on
side scatter; A: Positive correlation between CD38 positive percentages and the event levels on side scatter; B: Positive correlation
between CD34 and CD38 double positive percentages and the event levels on side scatter; C: Negative correlation between CD34 positive
but CD38 negative percentages and the event levels on side scatter. Cell marker positive percentages on different side scale levels were
also compared with ANOVA. * P<0.01 when compared to all other groups except for the groups marked with #, @ and §, which P values
are smaller than 0.01 when compared to the groups with the same symbols in D and smaller
than 0.05 in F.
cells were mainly located at high side scatter though a quite few total positive events were shown. This is
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consistent with ISHAGE definition for HSC numerated
by Flow Cytometry.  However, when CD38+ populations
were analyzed, their positive percentages negatively
correlated to side scatter levels. Since total CD34+ cell
percentages at lower side scatters (levels 1-3) were
similar and all above 90%, the CD38+ events at lower
side scatter could be confirmed as lymphoid stem cells
[17], [18]. Considering the populations with the most
CD34+CD38- events are at side scatter levels 2 and 3, the
uncultured HSC at very low and very high side scatter
are less primitive. Compared to the side scatter, the
distribution of primitive HSC on forward scatter is much
less variable. Only the population at very high level
(level 4) consistently exhibited remarkably increased
percentages of cells with differentiation markers and
decreased percentages of cells with stem cell markers.
To meet the increasing clinical requirements for large
amount of HSC, a great deal of effort has been made to
expand HSC by in vitro culture [19]-[27]. During the
expansion with current technologies, the HSC are
unavoidably undergoing to nonspecific differentiation or
losing stem cell markers [22], [27], resulting in the less
successful engraftment using expanded HSC when
compared to the same numbers of uncultured HSC [28],
[29]. In the quality and quantity evaluation of expanded
HSC, only a few investigators applied ISHAGE protocol
in which the side scatter level of HSC was considered.
None of studies has shown an analysis of the forward
scatter level of expanded stem cells [3], [19], [21]-[29].
The current study demonstrated that the expanded HSC
are more differentiated at higher side scatter and higher
forward scatter, suggesting that these two scatters can be
used as parameters to evaluate the differentiation status
of HSC following in vitro culture.
Some differentiated cells could lose the CD33 or
CD38 at the ending stage of the HSC development, but
this procedure occurs much later than the loss of CD34
[6], [7], [30]-[32].  Therefore, the CD34 and CD33 or
CD38 combined analyses in the current study could more
significantly demonstrate which cell populations are
more primitive, with the CD34+CD33- and CD34+CD38-
cells being more primitive HSC while CD34+CD33+ and
CD34+CD38+ cells would be at the early stage of the
differentiation mainly towards to myeloid linage and
lymphoid linage, respectively.
The in vitro expanded HSC usually contains very large
portion of nonspecifically differentiated cells [22], [27],
[29]. These differentiated cells could potentially affect
the efficacy of the stem cell transplantation. It was
reported that expanded HSC have less successful
engraftment [33], [34]. The purified primitive HSC may
be required in some HSC transplantation [35]-[40]. Thus,
it would be very important to isolate the less non-specific
differentiated HSC from the total expanded HSC.
Currently, the most common methods to isolate HSC
from the mixed cell population conjugate the cells with
magnetic beads or fluorescence-labeled antibodies. The
procedure is complicated, expensive, labor-intensive and
has an increased chance for contamination (also the
antibody itself could potentially affect the cells by cross-
linking receptors).  Our data showed that the population
at lower side scatter and forward scatter (levels 1 and 2)
contains the highest percentage of nonspecifically
differentiated HSC, which provides a possibility to
isolate relatively high primitive HSC using Flow
cytometry cell sorter without antibody conjugation.
Event distribution on side scatter and forward scatter
could be affected by the culture media and cytokines
with which HSC are cultured. TPO, Flt-3L, SCF and IL-
3 used in this study were also applied in most other HSC
expansion studies [19], [21]-[28]. In addition to
CellGro®Stem Cell Expansion Media, IMDM with 10%
FBS was also examined. The correlations between side
or forward scatters and stem cell or differentiation
markers are the same for  the cells cultured with IMDM
with 10% FBS as those with CellGro®Stem Cell
Expansion Media except for significantly increased
CD38 expression in former.
The distribution of differentiated HSC on the side
versus forward scatter dot plot is also related to culture
time. On day 0, the CD38+ percentages were negatively
correlated to side scatter levels, but on day 3 following
the culture, no significant correlation between them,
while on day 6 the correlation became positive. In
another study with the same expansion system but
different samples, the cells were cultured for 10 days.
The correlative relationship between CD38+ percentages
and side scatter levels was consistent to this study for the
first 6 days’ culture. On day 10 following the culture, the
CD38+ percentages on all side scatter levels became
much lower than before, but they were still positively
correlated, suggesting CD38+ cells become more
irregular following the culture. This might be resulted
from cell senescence.
We also noticed that the width of the grid (gate) could
affect the result. When the very narrow grids such as the
gates for uncultured HSC levels 1 to 3, were used to
analyze post-cultured HSC, the result for CD38 on
forward scatter could be different, clearly because area 4
on forward scatter includes a great portion of main
population, which leads the shift of positive percentages
at different forward scatter levels. Although the CD38+
percentage at forward scatter level 1 could be higher than
other levels in this case, the differences between different
levels are less than 2%, which does not make any
substantial effect on the primitive stem cell isolation.
Moreover, CD34+CD38- percentages are still negatively
correlated to forward scatter levels (r=-0.554, P<0.01).
Therefore, it can still be concluded that more primitive
HSC following in vitro culture are located at lower side
scatter and lower forward scatter, even though the
smaller gates were used for the analysis.
IV. CONCLUSION
The in vitro expanded HSC have tendency to increase
size and granularity and to spontaneously differentiate
into myeloid (CD33+) and lymphoid (CD38+) lineages.
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The changes of post-expaded HSC in morphology,
exhibited on flow cytometry plot as higher forward
scatter and higher side scatter, are positively correlated to
the increased CD33 and CD38 expression on these cells,
suggesting that the non-specific differentiation of in vitro
expanded HSC could be evaluated using flow cytometry
by examining the distribution of cell events on side
scatter and forward scatter.
Figure 7. CD34, CD33 and CD38 positive percentages correlate with event levels on forward scatter. CD34-positive HSC isolated from
G-CSF mobilized peripheral blood were in vitro cultured for 6 days. Cells from 10 cultures were triple-stained for flow cytometric
detection of CD45, CD34 and CD33 or CD38. A flow cytomtric dot plot (SS/FS) was divided into 4 areas on the side scatter and scaled
from 1 to 4 to show the scatter levels. Correlation charts were plotted by cell marker positive percentages versus forward scatter levels.
A: Positive correlation between CD33 positive percentages and the event levels on forward scatter; B: Positive correlation between CD34
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and CD33 double positive percentages and the event levels on forward scatter; C: Negative correlation between CD34 positive but CD33
negative percentages and the event levels on forward scatter; D: Negative correlation between total CD34 positive percentages and the
event levels on forward scatter; A: Positive correlation between CD38 positive percentages and the event levels. On forward scatter; B:
Positive correlation between CD34 and CD38 double positive percentages and the event levels on forward scatter; C: Negative correlation
between CD34 positive but CD38 negative percentages and the event levels on forward scatter. Cell marker positive percentages on
different forward scale levels were also compared with ANOVA. * P<0.01 when compared to all other groups.
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